Xcout IntelSign inSubscribe

BioHarvest Sciences Inc. competitors & alternatives

BHSTBiotechVancouver, Canada

The 12 closest competitors and alternatives to BioHarvest Sciences Inc. among biotech companies — ranked by similarity to what BioHarvest Sciences Inc. actually does, not by market-cap band.

$28.2MMarket cap
87Employees
12Competitors listed

Subscribe to see BioHarvest Sciences Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

BioHarvest Sciences Inc. at a glance

BioHarvest Sciences Inc. is a biotech company headquartered in Vancouver, Canada. It is publicly listed (BHST) with a market capitalisation of $28.2M. Xcout tracks 44 named people at BioHarvest Sciences Inc., including Ilana Belzer (Chief Operating Officer).

BioHarvest Sciences Inc. leadership

  • Ilana BelzerChief Operating Officer
  • Dr. Ilana BelzerChief Operating Officer
  • Bar DichterChief Financial Officer
  • Jared TurnerChief Sales Officer
  • Malkit AzachiVice President of Research & Development
  • David K. RyanVice President of Investor Relations & Secretary

38 more named people on record for BioHarvest Sciences Inc., with roles, board committees and tenure — see the full roster →

Top 12 BioHarvest Sciences Inc. competitors

Ranked by semantic similarity — how close each company is to BioHarvest Sciences Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

iBio, Inc.IBIO · BiotechSan Diego, United States
64% matchPublic

Similar biotech company

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

Market cap$63.3M
Employees16
iBio, Inc. competitors & alternatives →
GenScript1548.HK · BiotechChina
63% matchPublicAI 33/100 ▲Green 5/100 ▼

Similar biotech company

Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.

Market cap$12.6B
Employees5,568
PythonJavaC++JavaScriptDocker
GenScript competitors & alternatives →
Bora6472 · PharmaceuticalsTaipei City, Taiwan
63% matchPublic

Pharmaceuticals

Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.

Market cap$1.7B
Employees2,255
Bora competitors & alternatives →
BioVaxys Technology Corp.BVAXF · BiotechEtobicoke, Canada
70% matchPublic

Similar biotech company

BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.

Market cap$3.3M
Employees3
BioVaxys Technology Corp. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of BioHarvest Sciences Inc. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for BioHarvest Sciences Inc.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →